This invention relates to a wax composition comprising a plurality of fatty acid amide compounds having the Formula (I):

##STR00001##

where R.sup.1, R.sup.2, n.sub.1, n.sub.2, m.sub.1, and m.sub.2 are as described herein. This invention also relates to a wax composition comprising: a) one or more fatty acid amide compounds having the Formula (II):

##STR00002##

and b) one or more fatty acid amide compounds having the Formula (III):

##STR00003##

where R.sup.1, R.sup.2, n.sub.1, and n.sub.2 are as described herein. This invention also relates to a fatty acid amide compound having the Formula (I) and a process for preparing a compound of Formula (I).

A compound of formula (I),

##STR00001##

wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

A compound of formula (I),

##STR00001##

wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

A compound of formula (I), ##STR00001##
wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

A compound of formula (I), ##STR00001##
wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof: ##STR00001## The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

A compound of formula (I),

##STR00001##

wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

A compound of formula (I),

##STR00001##

wherein R.sup.1 is an optionally substituted aryl or an optionally substituted heteroaryl, R.sup.2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R.sup.3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention provides compounds, compositions thereof, and methods of using the same.